[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562274":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":56,"collaborators":25,"id":59,"slug":25,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sevoflurane sedation group","EXPERIMENTAL","Patients will undergo fiberoptic intubation under sevoflurane sedation.",[13],"Drug: Sevoflurane",{"label":15,"type":16,"description":17,"interventionNames":18},"Awake fiberoptic group","ACTIVE_COMPARATOR","Patients will undergo fiberoptic intubation with bilateral Superior Laryngeal Nerve block and Recurrent laryngeal nerve block.",[19],"Drug: 2% Xylocaine (2 ml )",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Sevoflurane",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"2% Xylocaine (2 ml )",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Marwa A Abogabal, MD","CONTACT","00201004190210","Dr_mora1985@med.tanta.edu.eg",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.00192,30.78847,{"lat":47,"lon":46},[50,51,54],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Mohamed Z Wfa, MD","PRINCIPAL_INVESTIGATOR",{"name":55,"role":53,"phone":25,"phoneExt":25,"email":25},"Laila A El-Ahwal, MD",{"type":53,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Marwa Ahmed Abogabal","Lecturer of Anesthesiology, Intensive Care and Pain, Faculty of Medicine, Tanta University, Tanta, Egypt.","100562274",false,"NCT06601036","Sevoflurane Sedation as an Alternative for Awake Fiberoptic Intubation in Difficult Airway Patients","Inclusion Criteria:\n\n* Age from 18 to 50 years.\n* Both sexes.\n* American Society of Anesthesiology (ASA) physical status I-II.\n* Patients with difficult airway (Mallampati grade 3 and 4 with mouth opening less than 5 cm).\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients with bleeding disorders and nasal mass.\n* Allergy or intolerance to one of the study medications.\n* Patients with uncontrolled systemic diseases.\n* patients with gastro-esophageal reflex.\n* history of nasopharyngeal surgery or drug abuse.","ALL","18 Years","50 Years",{"count":68,"type":69},70,"ESTIMATED","INTERVENTIONAL",[72],"NA","The aim of this study is to compare patient satisfaction and intubating conditions with fiber optic intubation under sevoflurane sedation versus airway blocks in difficult airway patients",[23,75,76,77],"Sedation","Awake Fiberoptic Intubation","Difficult Airway","2024-09-17",{"date":80,"type":81},"2024-09-19","ACTUAL",{"date":78,"type":81},{"date":84,"type":69},"2025-02-01",{"name":5,"class":6},1]